TRUMF:OTO-Terumo Corp. (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 17.132

Change

0.00 (0.00)%

Market Cap

USD 12.70B

Volume

2.86K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Terumo Corp is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. Its products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems & artificial organs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 104.77B
ESLOY Essilor International SA

N/A

USD 104.51B
HOCPF HOYA Corporation

N/A

USD 42.49B
HOCPY Hoya Corp

N/A

USD 41.61B
RSMDF Resmed Inc DRC

N/A

USD 31.08B
CLPBY Coloplast A

N/A

USD 27.81B
CLPBF Coloplast A/S

N/A

USD 27.53B
TRUMY Terumo Corp ADR

N/A

USD 25.37B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 21.79B
SAUHY Straumann Holding AG ADR

N/A

USD 20.74B

ETFs Containing TRUMF

DXJH 0.00 % 0.48 %

N/A

N/A
CNKY:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 56.37B
XDJP:LSE Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

N/A

USD 330.91B
SXRZ:F iShares VII PLC - iShares.. 0.00 % 0.00 %

+0.70 (+0.82%)

USD 55.89B
EXX7:XETRA iShares Nikkei 225 UCITS .. 0.00 % 0.00 %

+0.11 (+0.82%)

USD 28.25B
SXRZ:XETRA iShares VII PLC - iShares.. 0.00 % 0.00 %

+1.25 (+0.82%)

USD 58.15B
XDJE:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+0.31 (+0.82%)

USD 0.03B
XDJP:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+0.14 (+0.82%)

USD 157.79B
1329:TSE iShares Core Nikkei 225 E.. 0.00 % 0.00 %

+270.00 (+0.82%)

USD 1,529.93B
1330:TSE Nikko Nikkei 225 Listed 0.00 % 0.00 %

+280.00 (+0.82%)

USD 5,423.56B
1369:TSE DIAM Nikkei 225 0.00 % 0.00 %

+260.00 (+0.82%)

USD 451.27B
1578:TSE Listed Index Fund Nikkei .. 0.00 % 0.00 %

+20.00 (+0.82%)

USD 12.13B
1397:TSE SMDS SMDAM NIKKEI225 ETF 0.00 % 0.00 %

+320.00 (+0.82%)

USD 195.63B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.80% 79% B- 65% D
Dividend Return 138.43% 96% N/A 99% N/A
Total Return 146.24% 98% N/A 96% N/A
Trailing 12 Months  
Capital Gain 14.86% 88% B+ 74% C
Dividend Return 148.04% 97% N/A 99% N/A
Total Return 162.91% 95% A 95% A
Trailing 5 Years  
Capital Gain 14.21% 66% D+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.21% 60% D- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 2.21% 35% F 43% F
Dividend Return 25.80% 74% C 67% D+
Total Return 23.59% 100% F 93% A
Risk Return Profile  
Volatility (Standard Deviation) 30.02% 76% C+ 72% C
Risk Adjusted Return 85.94% 99% N/A 98% N/A
Market Capitalization 12.70B 90% A- 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.